Depends on whether FTO is driving tumorigenesis. A more advanced...

Depends on whether FTO is driving tumorigenesis. A more advanced cancer is driven by the aberrant expression of epitranscriptomic modulators (like FTO).

Chemoresistance has been linked multiple times to FTO expression.

It's likely that the patients who responded did so because the hyperdemethylase action of FTO was inhibited which decreased chemoresistance and enabled Clo/Flo to function. This is in conjunction with the potent effects of FTO inhibition on growth, metastasis, proliferation, energy metabolism, and other hallmark factors of cancer. In theory, an FTO inhibitor (Bisantrene) is kind of like hitting the reset button on chemotherapy as well as having alternative functions, allowing the cancer to become sensative again to treatment. That's why I believe you see this response.

I believe that these peoples cancer are super sensitive to FTO inhibition. Who knows what effect a more suitable FTO inhibitory regimen may have had on moderate or even low responders to FTO inhibition.